Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-1399
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
American Association for Cancer Research (AACR)